Education
About Us
Working with TipRanks
Follow Us
Promore Pharma AB (DE:8T00)
STUTTGART:8T00
8T00 Stock Chart & Stats
Day’s Range― - ―
52-Week Range€0.02 - €0.64
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€1.57M
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)714.00K
Price to Earnings (P/E)―
Beta2.51
Next Earnings
Jun 03, 2025EPS Estimate
-0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.18
Shares Outstanding25,943,077
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Promore Pharma AB News
8T00 FAQ
What was Promore Pharma AB’s price range in the past 12 months?
Promore Pharma AB lowest stock price was €0.02 and its highest was €0.64 in the past 12 months.
What is Promore Pharma AB’s market cap?
Promore Pharma AB’s market cap is €1.57M.
When is Promore Pharma AB’s upcoming earnings report date?
Promore Pharma AB’s upcoming earnings report date is Jun 03, 2025 which is in 5 days.
How were Promore Pharma AB’s earnings last quarter?
Currently, no data Available
Is Promore Pharma AB overvalued?
According to Wall Street analysts Promore Pharma AB’s price is currently Overvalued.
Does Promore Pharma AB pay dividends?
Promore Pharma AB does not currently pay dividends.
What is Promore Pharma AB’s EPS estimate?
Promore Pharma AB’s EPS estimate is -0.04.
How many shares outstanding does Promore Pharma AB have?
Promore Pharma AB has 25,943,077 shares outstanding.
What happened to Promore Pharma AB’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Promore Pharma AB?
Currently, no hedge funds are holding shares in DE:8T00
Company Description
Promore Pharma AB
Promore Pharma AB is a biopharmaceutical company specialized in the development of therapeutic peptides within the fields of wound care and scar prevention. The company aims to develop first-in-category pharmaceuticals for indications with high unmet medical needs. Its lead project is ensereptide (PXL01) which will be used for the prevention of post-surgical scarring and is being prepared for a clinical phase II trial for the prevention of the formation of unesthetic scars on the skin. Its second project is ropocamptide (LL-37), which has been recently evaluated in a clinical phase IIb study with positive results in patients with large venous leg ulcers (VLUs).